GLP1R and inflammatory bowel disease: As the prevalence of both IBD and T2DM continues to rise globally, and as indications for GLP-1–based therapies expand beyond glycemic control, these findings provide clinically relevant evidence supporting their broader metabolic and gastrointestinal safety.